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The mechanism of quinapril's interaction with the organic anion transporter was characterized by
studying its effect on the transport of p-aminohippurate (PAH) in rabbit renal basolateral mem-
brane vesicles (BLMV). Cis-inhibition studies demonstrated that quinapril was a specific and
potent inhibitor of PAH. The Ki of quinapril was about 20 fj.M, a value similar to that of probene-
cid and eight-times lower than the Km value of 165 nM for PAH. Even though quinapril resulted
in trans-inhibition of PAH uptake during counterflow studies, kinetic studies revealed that quinap-
ril was a competitive inhibitor of PAH transport. This latter finding suggests that quinapril and
PAH share a common binding site on the transporter. Overall, the results indicate that quinapril
is a high-affinity inhibitor of the organic anion transporter in renal BLMV, and that drug-drug
interactions may occur with other organic anions at the basolateral membrane of proximal cells.
KEY WORDS: competitive inhibition; p-aminohippurate; quinapril; kidney; basolateral
membrane vesicles.
INTRODUCTION
Angiotensin converting enzyme (ACE) inhibitors have proved to be
effective not only in patients with high renin hypertension but also in many
hypertension patients who have normal levels of plasma renin activity (1).
More recently, ACE inhibitors have played a prominent role in treating
patients with congestive heart failure, myocardial infarction, and diabetic
nephropathy. These drugs act by inhibiting conversion of the relatively inac-
tive angiotensin I to the potent vasoconstrictor angiotensin II, as well as by
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Fig. 1. Chemical structure of quinapril.
inhibiting the degradation of bradykinin, a potent vasodilator peptide. The
long-standing view of the renin-angiotensin-aldosterone (RAA) system is
that of a classical endocrine system in which circulating levels of hormone
are important. However, recent evidence suggests that this traditional view
is a gross oversimplification and should be expanded to include local (tissue)
RAA systems.
Quinapril (Fig. 1) is an ACE inhibitor that is formulated as an alkyl-
ester prodrug for improved bioavailability and drug performance (2). Once
absorbed, it is primarily de-esterified to its pharmacologically active metab-
olite, quinaprilat. Being an amphoteric drug (possessing an amino group,
pKa 5.4 and a carboxyl group, pKa 2.8), quinapril is completely ionized at
its carboxyl group and completely unionized at its amino group, at physio-
logical pH. Thus, quinapril is anionic in nature and would be expected to
utilize the organic acid transport system of proximal tubular cells. This con-
tention is supported by studies in the isolated perfused rat kidney (3,4) in
which substantial net transport was observed for quinapril across the baso-
lateral membrane, a process inhibited by organic anions (i.e., probenecid, p-
aminohippurate) but not by organic cations (tetraethylammonium, quinine).
Whole organ studies are limited, however, in that they describe only net
processes and do not provide a precise mechanistic basis for drug transport
at a single membrane.
It is important to characterize the renal handling of ACE inhibitors
since this route of elimination will not only influence access to RAA sites
in the kidney but may also impact on the drugs' systemic exposure and
potential for drug interactions. Thus, the renal uptake of quinapril was
characterized by studying its effect on the transport of p-aminohippurate




[3H]PAH (4.9 Ci/mmol) was purchased from DuPont-NEN (Boston,
MA). Quinapril and quinaprilat were gifts from Parke-Davis (Ann Arbor,
MI). Enalapril and enalaprilat were gifts from Merck (Rahway, NJ). All
other chemicals were of the highest purity available.
Membrane Preparation
Basolateral membrane vesicles (BLMV) were isolated from rabbit kid-
neys using a modification of the Percoll gradient method (5,6). A male New
Zealand White rabbit (2-3 kg) was anesthetized with xylazine (10mg/kg,
im) and ketamine (44 mg/kg, im). Kidneys were perfused in situ via the
renal artery with an ice-cold solution containing 140mM NaCl and 10mM
KCl. The kidneys were excised, decapsulated, and placed in an ice-cold per-
fusion solution. The cortex was removed, weighed, and minced. Typically,
about 10 g of tissue per rabbit were obtained. The minced cortex was homo-
genized in sucrose buffer (250 mM sucrose and 10 mM triethanolamine-
HCl, pH 7.6; 10 ml/g of tissue) using a glass-Teflon homogenizer (Glas-Col,
Model 099C K44) at speed setting 30 (-1400 rpm), 25 strokes. A 0.5 ml
aliquot of the homogenate was saved at 4°C for protein and marker enzyme
assays. Unless otherwise noted, the entire procedure was carried out on ice
or at 4°C. A Sorvall RC-5C Plus refrigerated centrifuge (SS-34 fixed-angle
rotor) was used for all centrifugations.
The homogenate was centrifuged at 3000 rpm for 10min. The super-
natant was saved, and the loose pellet was resuspended in half the original
volume of sucrose buffer, homogenized 10 strokes at speed setting 30, and
centrifuged at 3000 rpm for 10 min. The supernatants were combined and
centrifuged at 11,000 rpm for 15 min. The supernatant was saved for sub-
sequent use. The upper fluffy layer of the pellet was aspirated by a small
volume of supernatant (=1-2 ml) using a glass Pasteur pipette. The suspen-
sion of the fluffy pellet was further homogenized 10 strokes at speed setting
30, combined with the previously saved supernatant, and centrifuged at
18,000 rpm for 30 min. The upper fluffy layer of the pellet was resuspended
in 25 ml of fresh sucrose buffer and homogenized 10 strokes at speed setting
30. A 25 ml aliquot of fresh sucrose buffer was added to the homogenized
suspension and mixed. Each 25 ml of the resulting suspension was poured
into two centrifuge tubes containing 3.5ml of Percoll. A 1.5ml aliquot of
sucrose buffer was added to each tube to make a total volume of 30 ml. The
suspension was gently mixed and centrifuged at 20,000 rpm for exactly 1 hr
without a brake. The first 6 ml were discarded from the top of the resulting
Percoll gradient and the following 8 ml (7-14 ml fractions) were pooled as
crude basolateral membranes. The pooled fraction was centrifuged at
50,000 rpm for 1 hr (Beckman L8-70M ultracentrifuge, 70.1 Ti rotor). The
Percoll formed a glassy pellet and the membranes formed a fluffy pellet on
top of the Percoll. The fluffy pellet was resuspended in 8 ml of sucrose buffer
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using a syringe with a 25-gauge needle, and centrifuged at 50,000 rpm for
45min. The pellet was resuspended in 25ml of sucrose buffer. A 250 jul
aliquot of 1 M MgCl2 was added (final concentration l0mM). The suspen-
sion was stirred occasionally for 20 min and centrifuged at 5000 rpm for
15 min. The pellet was resuspended in 25 ml of sucrose buffer. Magnesium
was removed by adding 1.25 ml of 100 mM EDTA to make a final concen-
tration of 5 mM. The suspension was centrifuged at 20,000 rpm for 20 min.
The pellet was suspended in 25 ml of an appropriate loading buffer and
centrifuged at 20,000 rpm for 20 min. The resulting pellet, which contained
the purified basolateral membranes, was resuspended in a small volume of
loading buffer for transport studies using a syringe with a 25-gauge needle.
The BLMV were prepared the day before use, stored at 4°C overnight and
used within 3 days.
Marker Enzyme and Protein Assays
Na+/K+-ATPase, a marker for basolateral membranes, was determined
according to Jorgensen and Skou (7) with phosphate determined by the
method of Fiske and Subbarow (8). Orientation of BLMV was determined
by comparing total ATPase and Na+/K+-ATPase (ouabain sensitive)
activity in intact vesicles and those disrupted by the addition of deoxychol-
ate, as described by Goldinger et al. (6). Cross-contamination of BLMV
with brush border membranes was assessed by measuring the activity of
alkaline phosphatase (ALP) using a commercially available kit (Sigma Diag-
nostics, Kit no. 245, St. Louis, MO). Protein was measured according to the
method of Bradford (9) using y-globulin as standard.
Uptake Measurements
Uptake studies were conducted by a rapid filtration technique (10)
using a 10-place filtering manifold (Hoefer Scientific Instruments, San Fran-
cisco, CA). All transport measurements were made at 22°C. Typically,
BLMV were suspended in about 1-2 ml loading buffer to give a final protein
concentration of 10 mg/ml and incubated for 1 hr at room temperature
before uptake measurements. The reaction was initiated by adding 90 /il
uptake medium containing [3H]PAH (0.5 /iCi) and varying concentrations
of unlabeled PAH (± inhibitor) into a 10 jul vesicle suspension. At appropri-
ate times, the incubation was terminated by addition of 2 ml ice-cold stop
solution (200 mM mannitol, 50 mM K gluconate, and 10 mM Hepes,
pH 7.5). The contents were immediately filtered under vacuum through a
prewetted Millipore filter (PHWP, 0.3 /urn) and washed three times with 2 ml
ice-cold stop solution. The radioactivity remaining on the filters was
counted by standard liquid scintillation technique after dissolution in 8 ml
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scintillation cocktail (Ready Protein, Beckman Instruments, Fullerton, CA).
Correction for nonspecific binding was performed by running a zero time
in the presence of vesicles where radiolabeled substrate and stop solution
were added simultaneously. This value was subtracted from the uptake data.
Investigators have shown that PAH does not bind significantly (< 10%) to
the membrane vesicles (6,11), therefore [3H]PAH retained on the filters after
blank correction represents intravesicular PAH.
For studies in the presence of glutarate and an inwardly-directed Na+
gradient (i.e., Na+/glutarate-coupled PAH transport), vesicles were sus-
pended in buffer pH 7.5 containing 200 mM mannitol, 50 mM K gluconate,
and l0 mM Hepes. Uptake was initiated by mixing l0 jul vesicle suspension
with 90 ^l uptake medium, pH 7.5, containing [3H]PAH in 100 mM NaCl,
50 mM K gluconate, l0 mM Hepes, and 10 //M glutarate.
Uptake measurements conducted under voltage clamped conditions
were performed using the K+ ionophore, valinomycin, and equal concen-
trations of K+ on both sides of the membrane. Valinomycin stock solution
(1 mg/ml in ethanol) was added to the vesicle suspension 30 min before
uptake measurements for a final concentration of 3 jug/mg protein. Equal
volumes of ethanol were added in control experiments. The ethanol volume
was always less than 3% of the total.
For trans experiments, various test compounds were loaded into ves-
icles at the final step of membrane preparation. Uptake was then performed
in the absence of Na+ and glutarate gradients and under voltage clamped
conditions. Uptake medium was of the same composition as loading buffer
but without test compounds. For trans-experiments using a 10-fold dilution,
10 jul vesicle suspension was incubated with 90 n\ uptake medium containing
[3H]PAH. For subsequent studies using a 20-fold dilution, 10 nl vesicle sus-
pension was incubated with 190 /il uptake medium containing [3H]PAH.
Control uptakes were performed in unloaded vesicles.
Data Analysis
Unless otherwise specified, data are reported as mean ± standard devi-
ation from at least three different membrane preparations, with each prep-
aration conducted in triplicate. Statistical analyses were performed using a
Student's paired t test or ANOVA (SYSTAT v5.03, Systat, Inc., Evanston,
IL), as appropriate. Pairwise comparisons were made using Tukey's test.
A probability of p< 0.05 was considered statistically significant. Nonlinear
regression analysis was performed using SCIENTIST (v2.01, MicroMath
Scientific Software, Salt Lake City, UT) and a weighting factor of unity.
Goodness of fit was determined by evaluating the coefficient of determi-
nation (r2), the standard error of parameter estimates, and by visual inspec-
tion of the residuals.
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For dose-response studies, the inhibitory effect can be described by the
model
where E is the observed uptake, E0 is the uptake in the absence of inhibitor,
Imax is the maximum inhibition, I is the inhibitor concentration and IC50 is
the concentration that causes 50% inhibition of the maximal drug effect. If
the drug is capable of abolishing the uptake, then Imax= E0 and Eq. (1)
reduces to
The IC50 was estimated for each membrane preparation by fitting the data
to Eq. (2) using nonlinear regression.
For kinetic studies, the concentration-dependent uptake of PAH
reflected both saturable (i.e., Michaelis-Menten) and nonsaturable transport
processes
where Vmax is the maximal rate of saturable uptake, Km is the Michaelis
constant, Kd is the rate constant for a nonsaturable process and C is the
substrate (PAH) concentration. Kinetic parameters (i.e., Vmax, Km, and Kd)
of PAH uptake were estimated for each membrane preparation by fitting
the data to Eq. (3) using nonlinear regression.
The Michaelis-Menten equation was used to analyze the saturable
transport component [v= Uptake -Kd C= Vmax • C/(Km + C)], and is con-
veniently transformed into one that gives a straight line. This can be done
by taking the reciprocal of both sides of the equation to give
From a plot of 1/v vs. 1/C, Km and Vmax could then be estimated by linear
regression analysis.
Quinapril inhibited the saturable uptake of PAH in a competitive man-
ner (see Results section). For transport in the presence of a competitive
inhibitor, the kinetics become
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where Ki is the inhibition constant. Lineweaver-Burk transformation of Eq.
(5) gives
In the presence of a competitive inhibitor, the apparent value (Km.app) is
equal to Km (1+I/K i ) .
The Ki of quinapril was determined by three different approaches: (i)
by linear regression analysis of the Lineweaver-Burk plots of Eqs. (4) and
(6), (ii) by simultaneous fitting of the data to Eq. (5) using nonlinear
regression, and (iii) according to the method of Cheng and Prusoff (12);
thus, the Ki for a competitive inhibitor can be calculated from the known




Membrane vesicle preparations (±PAH) were evaluated with respect
to enzymatic activity or enrichment (n=23), contamination (n=24), and
orientation (n = 18). In particular, Na+/K+-ATPase activity in the isolated
BLMV was enriched 13.6 ± 5.5-fold whereas ALP activity was not enriched
(1.5 ± 0.4-fold). Analysis of vesicle orientation revealed 47.1 ± 10.5% right-
side-out, 11.1 ±2.6% inside-out, and 41.8 ± 10.8% open/leaky. Of the ves-
icles formed, over 80% were right-side-out. These values compare favorably
with those reported in the literature (6,13-19) and demonstrate that the
BLMV preparations were highly purified with negligible cross
contamination.
Kinetics of PAH Uptake
To obtain preliminary estimates of the kinetics for PAH, its initial rate
uptake (at 15 sec) was measured as a function of substrate concentration
(i.e., 10-1000 juM). As shown in Fig. 2, PAH uptake appeared nonlinear
and the data were best fit using a combination of saturable and nonsaturable
processes. According to Eq. (3), PAH had the following transport param-
eters: Vmax= 75.7± 16.6 pmol/mg per 15 sec, Km= 162 ± 13 jtM and Kd =
0.174 ± 0.047 jil/mg per 15 sec. For all analyses, the coefficient of determi-
nation (r2) was > 0.994. Comparison of the Vmax/Km vs. Kd suggests that,
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Fig. 2. Concentration-dependent uptake of PAH in BLMV. Membrane ves-
icles were suspended in buffer, pH 7.5 (200 mM mannitol, 50 mM K glucon-
ate, and 10 mM Hepes) and uptake was initiated in buffer, pH 7.5 (100 mM
NaCl, 50mM K gluconate, 10 mM Hepes, and 10 /iM glutarate). The 15-
sec uptake of [3H]PAH was measured in the presence of increasing concen-
trations of unlabeled drug. Data are X ± SE from three separate membrane
preparations. Lines were generated using fitted mean parameters (see text),
as determined by nonlinear regression analysis.
under linear conditions, the carrier-mediated component accounts for about
73% of the total PAH uptake and the nonsaturable process accounts for
about 27% of its uptake. However, at higher PAH concentrations the non-
saturable process makes a greater contribution to the overall transport
process.
Cis Effect of ACE Inhibitors on PAH Uptake
The interaction of select ACE inhibitors with the organic anion trans-
port system was investigated by determining the extent of cis inhibition on
PAH uptake. Cis refers to the inhibitor being present on the same side of
the membrane as radiolabeled PAH. The 15-sec uptake of PAH (50 pM)
was determined in the presence of an inwardly directed Na+ gradient and
10 juM glutarate, and in the presence of 1 mM of test inhibitors. As shown
in Fig. 3, quinapril markedly reduced the uptake of PAH to 30% of control
values and appeared to be as potent as probenecid (PRO), a model inhibitor
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Fig. 3. Cis effect of ACE inhibitors, probenecid (PRO) and tetraethylam-
monium (TEA) on PAH uptake in BLMV. Membrane vesicles were sus-
pended in buffer, pH 7.5 (200 mM mannitol, 50 mM K gluconate, and
10 mM Hepes) and uptake was initiated in buffer, pH 7.5 (100 mM NaCl,
50 mM K gluconate, 10 mM Hepes, and 10 j*M glutarate). The 15-sec
uptake of 50 ̂ M [3H]PAH was measured in the absence (control) and
presence of 1 mM various test inhibitors. Data are X ± SE from four separ-
ate membrane preparations. *p< 0.001 and **p< 0.0002, as compared to
control.
of organic anion transport. This result suggested that quinapril and probe-
necid effectively blocked the carrier-mediated transport of PAH since
uptake was reduced to that of the nonsaturable component. Of all ACE
inhibitors tested, quinapril exhibited the strongest inhibition. The inhibitory
potency of ACE inhibitors was as follows: quinapril > enalapril > quina-
prilat > enalaprilat. In contrast, tetraethylammonium (TEA), a model sub-
strate for organic cation transport, had no effect. It should be appreciated
that the inhibitory effect was specific since no compound altered the equilib-
rium value of PAH uptake (as measured at 1 hr).
Dose-Response Effect of Quinapril on PAH Uptake
The effectiveness of quinapril as an inhibitor of PAH uptake was con-
firmed by constructing a dose-response curve. The 15-sec uptake of PAH
(50 jiM) was measured in the presence of increasing concentrations of
inhibitor (i.e., 10-2000 juM). As shown in Fig. 4, quinapril inhibited PAH
uptake in a concentration-dependent manner. The IC50, as determined by
278 Akarawut and Smith
Fig. 4. Dose-response effect of quinapril on PAH transport in
BLMV. Membrane vesicles were suspended in buffer, pH 7.5
(200 mM mannitol, 50 mM K gluconate, and l0 mM Hepes) and
uptake was initiated in buffer, pH 7.5 (100 mM NaCl, 50 mM K glu-
conate, l0 mM Hepes, and 10 /iM glutarate). The 15-sec uptake of
50 nM [3H]PAH was measured in the presence of increasing concen-
trations of quinapril. Each data point is the mean of triplicate values
from a typical experiment and represents only the carrier-mediated
transport after correction for a nonsaturable component. The line
represents a best fit of the data using nonlinear regression analysis.
Eq. (2), was 24.7 ± 2.5 juM. For all analyses, the coefficient of determination
(r2) was >0.951. The inhibition constant (K i) of quinapril was then calcu-
lated from Eq. (7). Using known values for PAH concentration (50 jiM)
and Km (162 |iM), and individual IC50s for inhibitor from dose-response
curves, the Ki value for quinapril was estimated as 18.9 ± 1.9 /iM.
Effect of Quinapril on the Kinetics of PAH Uptake
The previous studies demonstrated that quinapril interacted with the
organic anion transporter by inhibiting the Na+/glutarate-coupled uptake
of PAH. This suggests that these two substrates could share a common
transport pathway. To further investigate the nature of this interaction, the
15-sec uptake kinetics of increasing concentrations of PAH were examined
alone and in the presence of 25 juM quinapril. As shown by the Lineweaver-
Burk plot in Fig. 5, a change was observed in the slope and x intercept of
the curve, but not y intercept in the presence of inhibitor. Kinetic analysis
(Table I) revealed a significant increase in the apparent Km of PAH
(161±35 juM for control vs. 428±202 juM in the presence of quinapril;
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Fig. 5. Lineweaver-Burk analysis of the effect of quinapril on PAH transport
in BLMV. Membrane vesicles were suspended in buffer, pH 7.5 (200 mM
mannitol, 50 mM K gluconate, and 10 mM Hepes) and uptake was initiated
in buffer, pH 7.5 (100 mM NaCl, 50 mM K gluconate, 10 mM Hepes, and
10 jjM glutarate). The 15-sec uptake of increasing concentrations of [3H]PAH
was measured alone and in the presence of 25 /iM quinapril. Data are X ± SE
from four separate membrane preparations and represent only the carrier-
mediated transport after correction for a nonsaturable component. Lines
were generated using fitted mean parameters (see Table I), as determined by
linear regression analysis.
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aValues are x± SD from four separate membrane preparations. Data were fit to Eqs.
(4) and (6) using linear regression.
bKm.app =Km(1+I/K i).
cKi = I/[(Km.app/Km)-1].
dp < 0.05, as determined using a Student's paired t test.
p < 0.05), whereas the value for Vmax was not altered (100 ± 20 pmol/mg per
15 sec for control vs. 98 ± 13 pmol/mg per 15 sec in the presence of quina-
pril). Thus, the mechanism of inhibition was clearly of a competitive type,
suggesting that quinapril and PAH share a common carrier. The Ki, as
estimated from this plot using Eqs. (4) and (6), was 17.3 ± 5.1 fiM.
Knowing the type of inhibition, kinetic parameters were confirmed by
fitting the data to a competitive inhibition model, as described by Eq. (5).
The parameter estimates (Km and Vmax) were comparable regardless of
whether PAH uptake data were evaluated alone (i.e., fit only control data
to a Michaelis-Menten equation) or by simultaneous fitting (Table II).
Moreover, these values were in close agreement with those obtained from
the Lineweaver-Burk plot. This analysis is graphically depicted in Fig. 6,
and Ki was estimated as 20.2 ± 3.5 juM. For all analyses, the coefficient of
determination (r2) was >0.878.
Ki values determined by all three approaches (i.e., Lineweaver-Burk,
nonlinear regression, dose-response) were in excellent agreement. Taken
together, the Ki of 20 ̂ iM for quinapril was approximately eight times lower
than the Km of PAH. Thus, it appears that quinapril is a high affinity sub-
strate for the basolateral organic anion transporter.
Trans Effect of Quinapril on PAH Uptake
The data indicate that quinapril is a potent competitive inhibitor of the
PAH transport system due to its ability to cis inhibit PAH/glutarate
exchange. Trans-stimulation is one of the criteria used to demonstrate the
involvement of a carrier or whether compounds share a common carrier.
Therefore, we further investigated whether quinapril was capable of trans-
stimulating [3H]PAH uptake, where trans refers to the presence of driving
substance on the side opposite to that of radiolabeled substrate. In these
experiments, [3H]PAH influx was measured in unloaded vesicles (control)
and in vesicles preloaded with high concentration of unlabeled PAH or qui-
napril under equal pH (in = out) and voltage clamped conditions. As shown
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Table II. Nonlinear Regression Analysis of the Kinetics of Quinapril Inhibition














aValues are X± SD from four separate membrane preparations. Data were fit to Eq. (5)
using nonlinear regression.
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PAH (MM)
Fig. 6. Simultaneous fit of the concentration-dependent uptake of PAH
in BLMV using a Michaelis-Menten equation and a competitive inhi-
bition model. Experimental conditions were as described in Fig. 5. Data
are X±SE from four separate membrane preparations and represent
only the carrier-mediated transport after correction for a nonsaturable
component. Lines were generated using fitted mean parameters (see
Table II), as determined by nonlinear regression analysis.
in Fig. 7A, PAH concentrations of 1 and 4 mM were capable of trans-
stimulating itself by 159 ±24% and 182 ±16% of control, respectively.
Although not statistically significant, quinapril (at 1 and 4 mM) showed
inhibitory effects with the uptake reduced to 58 ± 12% and 46 ± 14% of con-
trol, respectively. This trans effect by unlabeled PAH and quinapril was
specific since the equilibrium uptake of [3H]PAH (as measured at 1 hr) was
not affected when vesicles were preloaded with these drugs.
It is possible that the inhibition caused by quinapril was due to a sig-
nificant amount of the drug carried over from the uptake medium according
to our study design. For example, the final concentration would be 100 /iM
when vesicles preloaded with 1 mM quinapril were diluted 10-fold. This
residual amount of quinapril would be present on the cis face of the mem-
branes and could result in cis inhibition of [3H]PAH influx. To rule out
this possibility, we performed another experiment using vesicles loaded with
50 pM quinapril followed by a 20-fold dilution. Glutarate, an effective coun-
ter ion of PAH (20), was also tested. Similar to our previous results,
[3H]PAH uptake was enhanced to 120% and 153% of control by intravesicu-
lar PAH and glutarate, respectively, but was reduced to 65% of control in
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Fig. 7. Trans-effect of PAH, quinapril and glutarate on PAH uptake
in BLMV. Membrane vesicles were suspended in buffer, pH 7.5
(200 mM mannitol, 50 mM K gluconate, and 10 mM Hepes) without
loading compounds (control) or with unlabeled PAH (1 and 4 mM),
quinapril (1 and 4 mM), and glutarate (1 mM). Valinomycin was
added to the vesicles (3 /<g/mg protein) 30 min prior to the uptake
measurements. Uptake medium was of the same composition as
loading buffer but without test compounds. (A) Uptake was meas-
ured at 2 min by diluting vesicles 10-fold with uptake medium con-
taining 50 nM [3H]PAH. Data are x±SE (n= 3); *p<0.05, as
compared to control. (B) Experimental conditions were the same as
in Panel A except that vesicles were diluted 20-fold. Data are the
mean of triplicate values from one membrane preparation.
quinapril-loaded vesicles (Fig. 7B). Therefore, the observed trans effect by
quinapril was not a manifestation of cis inhibition.
DISCUSSION
Renal tubular secretion is a multistep process involving the uptake of
drug across the basolateral membrane, diffusion through the proximal cell,
and exit across the brush border membrane. Organic anion uptake has been
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characterized as a tertiary active transport (21,22). In this regard, Na+/K+-
ATPase creates an electrochemical potential difference for Na+ (out > in) at
the basolateral membrane. Dicarboxylates (i.e., cc-ketoglutarate) are then
cotransported with Na+ down its concentration gradient. Finally, a-keto-
glutarate is exchanged for an organic anion resulting in its net uptake. Com-
petitive inhibition among organic anions may occur at this tertiary step,
thereby altering the proportional relationship between plasma and urine
drug levels.
With notable exceptions, ACE inhibitors (including quinapril) are
cleared predominantly by the kidney. Yet, few studies have rigorously exam-
ined the precise mechanisms of renal transport for these drugs. Instead,
previous studies have defined the overall or net renal clearance of ACE
inhibitors using whole animal or isolated organ models. Renal clearance
models may, still, be further complicated by the substantial intrarenal
metabolism of ACE inhibitor prodrugs once they reach the intracellular
space of proximal tubular cells (3,4,23). As a result, we have characterized
the interaction of quinapril with the organic anion transporter by studying
its effect on the transport of PAH in BLMV. Studies in isolated basolateral
membranes are advantageous in that they are free from the influence of
intracellular events such as metabolism, sequestration, and binding. They
are also devoid of complicating extracellular events such as blood flow and
protein binding.
In the present study, we demonstrated that PAH transport is inhibited
strongly by quinapril and that this effect is specific since the equilibrium
value of PAH uptake is not altered. The IC50 and Ki values of quinapril (=25
and 20 /tM, respectively) are much lower than the Km of PAH (=165 jiM),
indicating that quinapril is a high-affinity inhibitor of the basolateral
organic anion transport system. Further, the drug is as potent as probene-
cid, a typical inhibitor of PAH transport. In this regard, the Ki of quinapril
falls within the range of values (K is of 15-50 /jM) reported in the literature
for probenecid (24-26). With respect to mechanism, kinetic studies reveal
that quinapril acts as a competitive inhibitor of PAH transport. This result
further verified that quinapril competes with PAH at the same binding site
for transport across the basolateral membrane into proximal cells. It should
be appreciated that the Km value of PAH (=165 ̂ M) determined in this
investigation was in good agreement with previous studies in kidney. Others
have reported Km values of 175 /iM in rat BLMV (27), 144 juM in bovine
BLMV (25), and 110 /iM in isolated rabbit proximal tubules (26,28). The
carrier-mediated component of PAH uptake estimated in this study (i.e.,
73% of total uptake) is similar to the 72% value reported in dog BLMV (29)
and the 70% value reported in isolated rabbit renal proximal tubules (26).
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In membrane vesicles, the definitive criteria for showing a compound
as a substrate for a specific transport system is the ability to exhibit both cis
inhibition and trans stimulation (30). In general, carrier-mediated transport
involves four steps (31): first, binding of the substrate at one face of the
membrane; second, translocation of the loaded carrier from one face of the
membrane to the other; third, dissociation of the substrate; and fourth,
reorientation of the empty carrier back to the opposite face of the mem-
brane. To secure trans stimulation, it is assumed that translocation is slow
relative to the binding and dissociation steps, and that migration of the
empty carrier is slow relative to migration of the loaded carrier. Thus, a
large concentration of substrate on one side of the membrane can accelerate
the transport of a smaller concentration of substrate present on the opposite
side of the membrane by increasing the availability of free carrier (i.e., trans
stimulation). Our results showing that high concentrations of PAH and glut-
arate inside the vesicles are capable of trans-stimulating [3H]PAH uptake
are consistent with this concept. In contrast, the lack of a trans stimulatory
effect by quinapril (at high and low concentrations) might suggest that the
drug binds to the transporter but is not translocated. In conflict with this
possibility, however, are the in vivo and organ perfusion studies (2-4,32)
clearly indicating that quinapril undergoes tubular secretion. In addition,
kinetic studies verifying quinapril as a competitive inhibitor of PAH con-
firmed that the two substrates share a common binding site. Finally, it
should be noted that the absence of trans stimulation for a substrate does
not necessarily mean that translocation does not occur. For example, coun-
terflow studies have revealed a lack of trans stimulation for N1-methylnic-
otinamide (NMN) by NMN and procainamide (PCA) by PCA in rabbit
renal BLMV (33). Trans inhibitory effects were observed for NMN by 1-
methy1-4-phenylpyridinium (MPP+) in canine renal BBMV (31). Neverthe-
less, it was subsequently demonstrated that MPP+ was indeed transported
in rabbit renal BBMV by a pathway shared by TEA and NMN (34).
Quinapril's high affinity for the organic anion transporter suggests that
potential drug-drug interactions may readily occur with other organic
anions. This belief is supported by an in vivo rat study (35) in which quina-
pril substantially increased cefdinir's area under the curve and half-life, but
decreased its clearance as a result of competition at the tubular anion trans-
porter. Captopril had similar effects on cefdinir pharmacokinetics, but of
lesser magnitude. Human studies have also suggested that many ACE
inhibitors are renally cleared by tubular secretion along with glomerular
filtration (2,32,36). They appear to utilize the nonspecific organic acid
secretory pathway and, as a result, probenecid pretreatment has been shown
to significantly reduce the renal clearance of captopril (37), enalapril, and
enalaprilat (38). Therefore, knowing the precise mechanism of renal dispo-
sition for quinapril is of clinical importance, and should prove valuable in
optimizing drug therapy while avoiding unwanted drug interactions.
In conclusion, quinapril is found to be a potent inhibitor of the Na+/
glutarate-coupled transport of PAH in rabbit renal BLMV. Quinapril's
affinity (Ki^20 juM) is on order of that for probenecid and was about eight
times higher than that for PAH (Km«165 /iM). Kinetic studies reveal that
quinapril acts as a competitive inhibitor of PAH, suggesting the two sub-
strates share a common binding site on the transporter. Overall, the results
indicate that quinapril is a high-affinity inhibitor of the organic anion trans-
porter in renal BLMV, and that drug-drug interactions may occur with
other organic anions at the basolateral membrane of proximal cells.
ACKNOWLEDGMENTS
We thank Dr. Marilyn Morris for help in the preparation of renal mem-
brane vesicles.
REFERENCES
1. E. K. Jackson and J. C. Garrison. Renin and angiotensin. In P. B. Molinoff, R. W.
Ruddon, and A. G. Gilman (eds.), The Pharmacologic Basis of Therapeutics, 9th ed.,
McGraw-Hill, New York, 1996, pp. 733-758.
2. A. N. Wadworth and R. N. Brogden. Quinapril: A review of its pharmacological proper-
ties, and therapeutic efficacy in cardiovascular disorders. Drugs 41:378-399 (1991).
3. A. R. Kugler, S. C. Olson, and D. E. Smith. Disposition of quinapril and quinaprilat in
the isolated perfused rat kidney. J. Pharmacokin. Biopharm. 23:287-305 (1995).
4. A. R. Kugler, S. C. Olson, and D. E. Smith. Tubular transport mechanisms of quinapril
and quinaprilat in the isolated perfused rat kidney: Effect of organic anions and cations.
J. Pharmacokin. Biopharm. 24:349-368 (1996).
5. V. Scalera, Y. Huang, B. Hildmann, and H. Murer. A simple isolation method for basal-
lateral plasma membranes from rat kidney cortex. Membrane Biochem. 4:49-61 (1981).
6. J. M. Goldinger, D. S. Khalsa, and S. K. Hong. Photoaffinity labeling of organic anion
transport system in proximal tubule. Am. J. Physiol. 247:C219-C227 (1984).
7. P. L. J0rgensen and J. C. Skou. Purification and characterization of (Na+K+)-ATPase in
preparations from the outer medulla of rabbit kidney. Biochim. Biophys. Ada 233:366-380
(1971).
8. C. H. Fiske and Y. Subbarow. The colorimetric determination of phosphorous. J. Biol.
Chem. 66:375-400 (1925).
9. M. M. Bradford. A rapid and sensitive method for the quantitation of microgram quantit-
ies of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254
(1976).
10. U. Hopfer, K. Nelson, J. Perrotto, and K. J. Isselbacher. Glucose transport in isolated
brush-border membrane from rat small intestine. J. Biol. Chem. 248:25-32 (1973).
11. J. Eveloff. p-Aminohippurate transport in basal-lateral membrane vesicles from rabbit
renal cortex: Stimulation by pH and sodium gradient. Biochim. Biophys. Ada 897:474-480
(1987).
12. Y.-C. Cheng and W. H. Prusoff. Relationship between the inhibition constant (Ki) and
the concentration which causes 50% inhibition (IC50) of an enzymatic reaction. Biochem.
Pharmacol. 22:3099-3108 (1973).
Competitive Inhibition of p-Arainohlppurate Transport by Quinapril 285
13. J. L. Kinsella, P. D. Holohan, N. I. Pessah, and C. R. Ross. Isolation of luminal and
antiluminal membranes from dog kidney cortex. Biochim. Biophys. Acta 552:468-477
(1979).
14. R. A. Reynolds, J. Wald, P. D. McNamara, and S. Segal. An improved method for iso-
lation of basolateral membranes from rat kidney. Biochim. Biophys. Acta 601:92-100
(1980).
15. M. I. Sheikh, U. Kragh-Hansen, K. E. Jorgensen, and H. Roigaard-Petersen. An efficient
method for the isolation and separation of basolateral-membrane and luminal-membrane
vesicles from rabbit kidney cortex. Biochem. J. 208:377-382 (1982).
16. E. F. Boumendil-Podevin and R. A. Podevin. Isolation of basolateral and brush border
membranes from the rabbit kidney cortex: Vesicle integrity and membrane sidedness of
the basolateral fraction. Biochim. Biophys. Acta 735:86-94 (1983).
17. Z. Talor, R. M. Gold, W. C. Yang, and J. A. L. Arruda. Anion exchanger is present in
both luminal and basolateral renal membranes. Eur. J. Biochem. 164:695-702 (1987).
18. S. H. Wright and T. M. Wunz. Succinate and citrate transport in renal basolateral and
brush border membranes. Am. J. Physiol. 253:F432-F439 (1987).
19. S. A. Hilden, C. A. Johns, W. B. Guggino, and N. E. Madias. Techniques for isolation of
brush-border and basolateral membrane vesicles from dog kidney cortex. Biochim. Biophys.
Acta 983:77-81 (1989).
20. J. B. Pritchard. Coupled transport p-aminohippurate by rat kidney basolateral mem-
brane vesicles. Am. J. Physiol. 255:F597-F604 (1988).
21. D. C. Brater, P. P. Sokol, S. D. Hall, and T. D. McKinney. Disposition and dose require-
ments of drugs in renal insufficiency. In D. W. Seldin and G. Giebisch (eds.), The Kidney:
Physiology and Pathophysiology, 2nd ed., Raven, New York, 1992, pp. 3671-3695.
22. J. B. Pritchard and D. S. Miller. Proximal tubular transport of organic anions and cations.
In D. W. Seldin and G. Giebisch (eds.), The Kidney: Physiology and Pathophysiology, 2nd
ed., Raven, New York, 1992, pp. 2921-2945.
23. I. A. M. de Lannoy, R. Nespeca, and K. S. Pang. Renal handling of enalapril and enala-
prilat: Studies in the isolated red blood cell-perfused rat kidney. J. Pharmacol. Exp.
Ther. 251:1211-1222(1989).
24. K. J. Ullrich, G. Rumrich, and S. Kloss. Contraluminal organic anion and cation transport
in the proximal renal tubule: V. Interaction with sulfamoyl- and phenoxy diuretics, and
with /5-lactam antibiotics. Kidney Int. 36:78-88 (1989).
25. C. Schmitt and G. Burckhardt. p-Aminohippurate/2-oxoglutarate exchange in bovine
renal brush-border and basolateral membrane vesicles. Pflilgers Arch. 423:280-290 (1993).
26. S. Shpun, K. K. Evans, and W. H. Dantzler. Interaction of ee-KG with basolateral organic
anion transporter in isolated rabbit renal S3 proximal tubules. Am. J. Physiol. 268:F1109-
Fl 116 (1995).
27. D. A. Griffiths, S. D. Hall, and P. P. Sokol. Interaction of 3'-azido-3'-deoxythymidine
with organic ion transport in rat renal basolateral membrane vesicles. J. Pharmacol. Exp.
Ther. 257:149-155 (1991).
28. W. H. Dantzler, K. K. Evans, and S. H. Wright. Kinetics of interactions of para-aminohip-
purate, probenecid, cysteine conjugates and N-acetyl cysteine conjugates with basolateral
organic anion transporter in isolated rabbit proximal renal tubules. J. Pharmacol. Exp.
Ther. 272:663-672 (1995).
29. F. G. M. Russel and W. G. Vermeulen. Effect of substituted benzoylglycines (hippurates)
and phenylacetylglycines on p-aminohippurate transport in dog renal membrane vesicles.
Pharm. Res. 11:1829-1833 (1994).
30. P. D. Holohan and C. R. Ross. Mechanisms of organic cation transport in kidney plasma
membrane vesicles: 1. Countertransport studies. J. Pharmacol. Exp. Ther. 215:191-197
(1980).
31. P. P. Sokol, P. D. Holohan, and C. R. Ross. The neurotoxins l-methyl-4-phenylpyridinium
and l-methyl-4-phenyl-l)2,3,6-tetrahydropyridine are substrates for the organic cation
transporter in renal brush border membrane vesicles. J. Pharmacol. Exp. Ther. 242:152-
157(1987).
286 Akarawut and Smith
Competitive Inhibition of p-Aminohippurate Transport by Quinapril 287
32. E. J. Begg, R. A. Robson, R. R. Bailey, K. L. Lynn, G. J. Frank, and S. C. Olson. The
pharmacokinetics and pharmacodynamics of quinapril and quinaprilat in renal impair-
ment. Br. J. Clin. Pharmacol. 30:213-220 (1990).
33. P. P. Sokol and T. D. McKinney. Mechanism of organic cation transport in rabbit renal
basolateral membrane vesicles. Am. J. Physiol. 258:F1599-F1607 (1990).
34. K.. D. A. Lazaruk and S. H. Wright. MPP* is transported by the TEA+-H+ exchanger
of renal brush-border membrane vesicles. Am. J. Physiol. 258:F597-F605 (1990).
35. A. Jacolot, M. Tod, and O. Petitjean. Pharmacokinetic interaction between cefdinir and
two angiotensin-converting enzyme inhibitors in rats. Antimicrob. Agents Chemother.
40:979-982 (1996).
36. J. B. Kostis, J. J. Raia, Jr., E. A. DeFelice, J. A. Barone, and R. G. Deeter. Comparative
clinical pharmacology of ACE inhibitors. In J. B. Kostis and E. A. DeFelice (eds.), Angio-
tensin Converting Enzyme Inhibitors, Alan R Liss, New York, 1987, pp. 19-54.
37. S. M. Singhvi, K. L. Duchin, D. A. Willard, D. N. KcKinstry, and B. H. Migdalof. Renal
handling of captopril: Effect of probenecid. Clin. Pharmacol. Ther. 32:182-189 (1982).
38. F. H. Noormohamed, W. R. McNabb, and A. F. Lant. Pharmacokinetic and pharmacody-
namic actions of enalapril in humans: Effect of probenecid pretreatment. J. Pharmacol.
Exp. Ther. 253:362-368 (1990).
